Welcome
Shenzhen Tianyuan Pharmaceutical Technology Co., Ltd
Tianyuan pharmaceutical company in Zhangjiang Eastern has built 500 square meters of pilot laboratories, equipped with two sets of 50L glass reactor, four sets of 100L double reactor, six sets of 50L rotary evaporator and matching heating and cooling equipment, to complete the 10kg Pilot complex experiments in complex compounds in Jiaozhou, Qingdao, a steady cooperation of the amplification plant, from 100kg to the tonnage of the enlarged production.
Our Main Produts
Intermediate
Welcome To Tianyuan Pharmaceutical
Shenzhen Tianyuan Pharmaceutical Technology Co., Ltd. is a manufacturer specializing in targeted anticancer drug research and is devoted to researching, manufacturing and marketing medical raw materials. The company’s main products are crizotinib, afatinib, Capmatinib, Aloitinib, Sorafenib, Ibrutinib, Laurodeinib and many other kinds of TINI API and intermedaites.
Atosiban Acetate: A Selective Oxytocin Receptor Antagonist for Research and Clinical Applications
Atosiban Acetate is a synthetic peptide that functions as a selective oxytocin receptor antagonist. It is widely recognized in pharmaceutical research for its ability to inhibit uterine contractions by blocking the action of oxytocin, a hormone responsible for stimulating labor. Due to its unique pharmacological properties, Atosiban Acetate 90779-69-4 has become an important compound in…
Dihexa 1401708-83-5: A Promising Research Peptide for Neuroscience
Dihexa 1401708-83-5 is a synthetic peptide derivative of angiotensin IV that has attracted significant attention in neuroscience research. Originally developed to investigate treatments for cognitive impairment and neurodegenerative disorders, Dihexa has demonstrated promising activity in preclinical studies. Although it is not approved for medical or therapeutic use, researchers continue to study its unique mechanism of…
Petrelintide: Advancing the Future of Obesity Treatment
Obesity has become one of the most significant public health challenges worldwide, driving increased demand for innovative therapies that can support long-term weight management. Among the promising candidates currently under development is Petrelintide 2766385-23-1, a next-generation peptide therapeutic identified by CAS Number 2766385-23-1. Designed as a selective amylin receptor agonist, Petrelintide is being investigated for…
Shenzhen Tianyuan Pharmaceutical Technology 